A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

April 23, 2021

Study Completion Date

April 23, 2021

Conditions
Palmoplantar Pustulosis
Interventions
BIOLOGICAL

Imsidolimab

Administered by subcutaneous injection once a month

DRUG

Placebo

Administered by subcutaneous injection once a month

Trial Locations (39)

10117

Investigational Site, Berlin

10789

Investigational Site, Berlin

19055

Investigational Site, Schwerin

20253

Investigational Site, Hamburg

22391

Investigational Site, Hamburg

28405

Investigational Site, Wilmington

33028

Investigational Site, Pembroke Pines

33155

Investigational Site, Miami

33316

Investigational Site, Fort Lauderdale

33607

Investigational Site, Tampa

35233

Investigational Site, Birmingham

43230

Investigational Site, Columbus

46168

Investigational Site, Plainfield

46250

Investigational Site, Indianapolis

48109

Investigational Site, Ann Arbor

48455

Investigational Site, Bad Bentheim

53127

Investigational Site, Bonn

63110

Investigational Site, St Louis

63117

Investigational Site, St Louis

66215

Investigational Site, Overland Park

73071

Investigational Site, Norman

75230

Investigational Site, Dallas

85032

Investigational Site, Phoenix

90405

Investigational Site, Santa Monica

91436

Investigational Site, Encino

97239

Investigational Site, Portland

Unknown

Investigational Site, Surrey

Investigational Site, Greater Sudbury

Investigational Site, Markham

Investigational Site, Drummondville

Investigational Site, Montreal

80-546

Investigational Site, Gdansk

40-611

Investigational Site, Katowice

90-265

Investigational Site, Lodz

10-229

Investigational Site, Olsztyn

27-400

Investigational Site, Ostrowiec Świętokrzyski

35-055

Investigational Site, Rzeszów

70-332

Investigational Site, Szczecin

50-566

Investigational Site, Wroclaw

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY